title: Formulation of dacarbazine-loaded Cubosomes--part II: influence of process parameters.
abstract: The purpose of this study is to investigate the combined influence of process parameters (independent variables) such as homogenization speed (X(1)), duration (X(2)), and temperature (X(3)) during the preparation of dacarbazine-loaded cubosomes. Box-Behnken design was used to rationalize the influence of these three factors on two responses, namely particle size (Y(1)) and encapsulation efficiency (Y(2)). Independent and dependent variables were analyzed with multiple regressions to establish a full-model second-order polynomial equation. F value was calculated to confirm the omission of insignificant parameters or interactions of parameters from the analysis to derive a reduced-model polynomial equation to predict the Y(1) and Y(2) of dacarbazine-loaded cubosomes. Pareto charts were also obtained to show the effects of X(1), X(2), and X(3) on Y(1) and Y(2). For Y(1), there was a model validated for more accurate prediction of response parameter by performing checkpoint analysis. The optimization process and Pareto charts were obtained automatically and they predicted the levels of independent parameters X(1), X(2), and X(3) (0.889794, 0.11886, and 0.56201, respectively) and minimized Y(1). The optimal process parameters (homogenization's speed = approximately 24,000 rpm, duration = 5.5 min, and temperature = 76 degrees C) led to the production of cubosomes with 85.6 nm in size and 16.7% in encapsulation efficiency. The Box-Behnken design proved to be a useful tool in the preparation and optimization of dacarbazine-loaded cubosomes. For encapsulation efficiency (Y(2)), further studies are needed to enhance the result and improve the model for such water-soluble drug encapsulation in cubosomes.
authors.affiliation: Division of Pharmaceutical Sciences, University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri 64110-2499, USA.
authors.forename: Di
authors.initials: D
authors.lastname: Bei
authors.forename: Jacob
authors.initials: J
authors.lastname: Marszalek
authors.forename: Bi-Botti C
authors.initials: BB
authors.lastname: Youan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D003606:Dacarbazine / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding; D005079:Excipients; D046529:Microscopy, Electron, Transmission; D015233:Models, Statistical; D053758:Nanoparticles; D010316:Particle Size
chemical_list: D000970:Antineoplastic Agents; D005079:Excipients; D003606:Dacarbazine
references.citation: Eur J Pharm Sci. 2006 Jan;27(1):44-53
references.pmid: 16157479
references.citation: AAPS PharmSciTech. 2008;9(4):1092-6
references.pmid: 18850275
references.citation: AAPS PharmSciTech. 2009;10(3):1032-9
references.pmid: 19669896
references.citation: Biol Pharm Bull. 2007 Feb;30(2):350-3
references.pmid: 17268078
references.citation: Int J Cosmet Sci. 2007 Oct;29(5):335-52
references.pmid: 18489367
references.citation: Colloids Surf B Biointerfaces. 2004 Apr 15;34(4):253-8
references.pmid: 15261065
references.citation: J Colloid Interface Sci. 2003 Apr 15;260(2):404-13
references.pmid: 12686193
references.citation: Langmuir. 2008 Mar 18;24(6):2573-9
references.pmid: 18247638
references.citation: Nano Lett. 2005 Aug;5(8):1615-9
references.pmid: 16089498
references.citation: Pharmacol Rev. 2001 Jun;53(2):283-318
references.pmid: 11356986
references.citation: Ann Oncol. 2006 Apr;17(4):563-70
references.pmid: 16418308
references.citation: AAPS PharmSciTech. 2007 Oct 19;8(4):E86
references.pmid: 18181547
references.citation: Langmuir. 2005 Mar 15;21(6):2569-77
references.pmid: 15752054
references.citation: Nature. 1968 Nov 2;220(5166):485-8
references.pmid: 5686165
references.citation: AAPS PharmSci. 2003 Nov 18;5(4):E30
references.pmid: 15198518
references.citation: Eur J Pharm Biopharm. 2006 Jun;63(2):128-33
references.pmid: 16497495
references.citation: Int J Pharm. 2007 Feb 1;329(1-2):150-7
references.pmid: 16987623
references.citation: Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):229-50
references.pmid: 11311994
references.citation: AAPS PharmSciTech. 2009;10(1):193-8
references.pmid: 19238555
references.citation: J Am Chem Soc. 2002 Oct 16;124(41):12255-60
references.pmid: 12371867